Individual expanded access, sometimes known as compassionate use, is a regulatory pathway that allows patients with serious or life-threatening conditions, such as cancer, to gain access to investigational drugs, biologics, or medical devices outside of clinical trials. This pathway is typically considered when no satisfactory alternative treatment options are available and when the patient is not eligible for ongoing clinical trials.
